This observation was reproduced in other triple negative breast cancer lines (MDA-MB-468 and HDQ-P1) that were treated with a previously validated pool of siRNAs targeting BRG1 [22, 27] (Figure 1G–1H). The gene discussed is SMARCA4; the disease is triple-negative breast carcinoma.